Title
Category
Credits
Event date
Cost
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Medical Moment Two: Expert Insight on Applying the ADAURA Results to Treatment of Early-Stage NSCLC Patients 
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Medical Moment One: Expert Insight on Practical Aspects of Molecular Profiling for Early-Stage NSCLC Cancers 
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
As the treatment paradigm for bladder cancer continuously evolves, all members of the oncology healthcare team must be equipped to evolve with it to ensure optimal patient care. With this evolution comes many questions for the bladder cancer treatment team. Join Drs. Neal Shore, Arjun Balar, Lidia Lopez, and Nurse Joanie Pfahl as they examine the new paradigm of bladder treatment using ICIs, and discuss the important role of each person on the treatment team.
  • Oncology
  • ANCC
  • Participation
$0.00
Nurse and physician expert faculty will discuss the emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Heart failure is a major public-health problem resulting in substantial morbidity and mortality for the US. Unfortunately, challenges and barriers to effective use of guideline-directed medical therapies (GDMT) among hospitalized patients with HFrEF remain. Join Drs. Muthiah Vaduganathan and Amulya Nagarur as they discuss practical strategies and insights into using GDMT, and opportunities for multidisciplinary partnerships when treating these patients.Supported through an independent educational grant from Merck.
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Join Drs. Muthiah Vaduganathan and Javed Butler for this on-demand online activity, as they examine novel methodologies to address the clinical worsening of HFrEF, with a focus on recently-reported results from the VICTORIA trial.Supported through an independent educational grant from Merck.
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Initiating and optimizing in-hospital guideline-directed medical therapies (GDMT) remains a challenge for clinicians treating patients with worsening HFrEF. Join Drs. Muthiah Vaduganathan and Michelle Kittleson, as they discuss opportunities and strategies to employ evidence-based therapies to address these challenges.Supported through an independent educational grant from Merck.
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
This educational activity is targeted to pediatric neurologists, neuro-oncologists, neurosurgeons, and other members of the multidisciplinary NF1 care team.
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Attendees of this educational activity will gain an appreciation of the genes involved in the DNA damage response pathways and their role in tumorigenesis, the latest guidelines on genetic testing/counseling for mutations in this pathway, and the clinical implications of testing results (such as the use of PARP inhibitor for treatment). There will also be extensive discussion about the evolving role of the OB/GYN practitioner in genetic testing/counseling and management of ovarian cancer survivors on PARP inhibitor therapy.Presented by Creative Educational Concepts, Inc.
  • Gastrointestinal
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
The implementation of molecular testing, especially analysis of human epidermal growth factor receptor 2 (HER2) status, has had a significant impact on clinical practice and patient care. Join Drs. David Ilson and Michael Press for this on-demand online activity, as they discuss assessment of HER2-mutant disease from each of their unique perspectives.Supported through an independent educational grant from AstraZeneca and Daiichi Sankyo. 

Pages